| Company Name: |
Changsha Fuzhen Biotechnology Co.，LTD Gold
|
| Tel: |
13823398 13823398779 |
| Email: |
3062105966@qq.com |
| Products Intro: |
Product Name:SCO-267
CAS:1656261-09-4
Purity:98% HPLC Package:10mg，50mg，100mg，1g，5g
|
| Company Name: |
ShangHai Biochempartner Co.,Ltd
|
| Tel: |
177-54423994 17754423994 |
| Email: |
2853530910@QQ.com |
| Products Intro: |
Product Name:SCO-267
CAS:1656261-09-4
Purity:98% HPLC LCMS Package:100MG;1G
|
| Company Name: |
Changzhou Chenhong Biotechnology Co., Ltd.
|
| Tel: |
+86-0519-85788828 +86-13775037613 |
| Email: |
sales@chemrenpharm.com |
| Products Intro: |
Product Name:SCO-267
CAS:1656261-09-4
Purity:99% Package:50mg;100mg;250mg;500mg;1g;5g
|
|
| | SCO-267 Basic information |
| Product Name: | SCO-267 | | Synonyms: | SCO-267;4-Pyridinepropanoic acid, β-cyclopropyl-2-[[1-[2-[[(2,2-dimethylpropyl)(6-methyl-2-pyridinyl)amino]carbonyl]-5-methoxyphenyl]-4-piperidinyl]methoxy]-, (βS)- | | CAS: | 1656261-09-4 | | MF: | C36H46N4O5 | | MW: | 614.79 | | EINECS: | | | Product Categories: | | | Mol File: | 1656261-09-4.mol |  |
| | SCO-267 Chemical Properties |
| Boiling point | 792.7±60.0 °C(Predicted) | | density | 1.201±0.06 g/cm3(Predicted) | | pka | 4.11±0.10(Predicted) | | form | Solid | | color | Off-white to light yellow |
| | SCO-267 Usage And Synthesis |
| Description | SCO-267 is a novel GPR40 full agonist, improving liver parameters in a mouse model of nonalcoholic fatty liver disease without affecting glucose or body weight. | | Uses | SCO-267 is an allosteric GPR40 full agonist. SCO-267 can be used for the research of chronic diseases including diabetes[1]. | | in vivo | SCO-267 (1 or 10 mg/kg; p.o.) improves insulin sensitivity and exerts sustained glucose-lowering effect[1]. | Animal Model: | N-STZ rats[1] | | Dosage: | 1 or 10 mg/kg | | Administration: | P.o.; | | Result: | Improved insulin sensitivity and exerted sustained glucose-lowering effect.
|
| | References | [1] Koyama R, et al. Chronic Exposure to SCO-267, an Allosteric GPR40 Full Agonist, Is Effective in Improving Glycemic Control in Rats. Mol Pharmacol. 2021 Apr;99(4):286-293. DOI:10.1124/molpharm.120.000168 |
| | SCO-267 Preparation Products And Raw materials |
|